Haematologica, Vol 92, Issue 6, 744-752 doi:10.3324/haematol.10869
Copyright © 2007 by Ferrata Storti Foundation
Ulrike Bacher ,
Torsten Haferlach ,
Wolfgang Kern ,
Claudia Haferlach ,
Susanne Schnittger
Copyright © 2007 by Ferrata Storti Foundation
Acute Myeloid Leukemia |
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
From the Bone Marrow Transplant Unit, University Hospital of Hamburg-Eppendorf, Hamburg, Germany (UB); MLL, Munich Leukemia Laboratory, Munich, Germany (TH, WK, CH, SS)
Correspondence: Susanne Schnittger, MLL, Munich Leukemia Laboratory, Max-Lebsche-Platz 31 81377 Munich, Germany. E-mail: susanne.schnittger{at}mll-online.com
Background and Objectives: The precise relationship between myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is unclear and the role of molecular mutations in leukemic transformation in MDS is controversial. The aim of this study was to clarify the relationship between AML and MDS by comparing the frequency of molecular mutations in the two conditions.
Design and Methods: We compared the frequency of FLT3-length mutations (FLT3-LM), FLT3-TKD, MLL-partial tandem duplications (MLL-PTD), NRAS, and KITD816 in 381 patients with MDS refractory anemia with excess blasts [RAEB] n=49; with ringed sideroblasts [RARS] n=310; chronic monomyelocytic leukemia [CMML] n=22) and in 4130 patients with AML (de novo: n=3139; secondary AML [s-AML] following MDS: n=397; therapy-related [t-AML]: n=233; relapsed: n=361).
Results: All mutations were more frequent in s-AML than in MDS and all but the FLT3-TKD were more frequent in RAEB than in RA/RARS. The higher incidences in s-AML were significant for FLT3-TKD (p=0.032), MLL-PTD (p=0.034), and FLT3-LM (RA/RARS: 0/45; RAEB: 8/293; 2.7%; s-AML: 45/389; 11.6%; p<0.0001). The incidence of NRAS-mutations increased from 17/272 (6.3%) in MDS to 41/343 in s-AML (12.0%) and that of KITD816-mutations from 2/290 (0.7%) to 5/341 (1.5%) (p=n.s.). FLT3-LM-acquisition occurred in 3/22 cases (13.6%) during MDS transformation; NRAS-acquisition occurred in 1/24 (4.2%). FLT3-LM and MLL-PTD were more frequent in AML relapse than in de novo AML or s-AML (p<0.0001).
Interpretation and Conclusions: The increase of molecular mutations from low- to high-risk MDS, to s-AML, and to relapsed AML emphasizes the value of these mutations as markers of progressing disease. Finally, we found a low rate of 5q- in the molecularly mutated cases in MDS which might explain the stability of this subtype.
Key words: myelodysplastic syndromes (MDS), acute myeloid leukemias (AML), molecular mutations, progression, leukemogenesis.
Related Article
Haematologica 2007 92: 723-727.
This article has been cited by other articles:
 |
|
 |
|
  A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Tiu, L. P. Gondek, C. L. O'Keefe, J. Huh, M. A. Sekeres, P. Elson, M. A. McDevitt, X. F. Wang, M. J. Levis, J. E. Karp, et al. New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5219 - 5226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Konrad, A. Karger, H. Hackl, I. Schwarzinger, I. Herbacek, and R. Wieser Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes J. Leukoc. Biol., October 1, 2009; 86(4): 813 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Chung, C. W. Choi, C. Slape, T. Fry, and P. D. Aplan Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell PNAS, September 16, 2008; 105(37): 14088 - 14093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Slape, L. Y. Liu, S. Beachy, and P. D. Aplan Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl Blood, September 1, 2008; 112(5): 2017 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia Blood, May 1, 2008; 111(9): 4797 - 4808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia Haematologica, June 1, 2007; 92(6): 723 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 392 - 397. [Abstract] [Full Text] [PDF]
|
|